

## 12-4264: Cleaved PARP (Asp214) (Clone: H8) rabbit mAb

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	PARP-H8
<b>Application :</b>	FACS, WB
<b>Reactivity :</b>	Human
<b>Conjugate :</b>	Unconjugated
<b>Format :</b>	Purified
<b>Alternative Name :</b>	Poly [ADP-ribose] polymerase 1, PARP-1, ADP-ribosyltransferase diphtheria toxin-like 1, ARTD1, NAD(+) ADP-ribosyltransferase 1, ADPRT 1
<b>Isotype :</b>	Rabbit IgG1k
<b>Immunogen Information :</b>	A synthetic peptide corresponding to residues surrounding Asp214 of human PARP

### Description

Poly-ADP-ribose polymerase 1 (PARP-1), is a substrate of caspase-3 and caspase-7, both of which play a dominant role in apoptosis. PARP is cleaved into 89 and 24 kDa fragments at Asp214. The detection of these fragments is used as an indicator of caspase activation and apoptosis induction for many cell lines. Under normal conditions, PARP aids in the detection and repair of DNA damage. With 1-2 million copies per nucleus, PARP is also involved in poly (ADP-ribosyl)ation, a post-translational protein modification mechanism used to modify chromatin structure and regulate transcription. Decreased PARP activity has been shown to lead to loss of memory and neuronal cell death.

### Product Info

<b>Amount :</b>	20 µl / 200 µl
<b>Content :</b>	1X PBS, 0.02% NaN <sub>3</sub> , 50% Glycerol, 0.1% BSA
<b>Storage condition :</b>	Store at -20°C. Avoid repeated freeze and thaw cycles.

### Application Note

1 Åµg/mL - 0.001 Åµg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.(0.5mg/ml, more than 200 western blots)




Fig-1: Flow cytometric analysis of SK.N.MC cells unstained untreated cells as negative control (blue) or stained untreated (red) or treated with staurosporine (green) using PARP Cleaved (Asp214) antibody PARP-H8 at 0.1 µg/mL.




Fig 2 : Western blot analysis of HeLa cell extract untreated or treated with Staurosporine using Cleaved PARP (Asp214) antibody PARP-H8 at 0.001 µg/mL.




Fig-3: Peptide blocking flow cytometric analysis of SK.N.MC cells secondary antibody only negative control (light blue) or untreated (red) or treated with staurosporine (green) or untreated and blocked with immunogen peptide (black) or treated and blocked with immunogen peptide (gold) or untreated and blocked with irrelevant peptide (dark blue) or treated and blocked with irrelevant peptide (purple) using PARP Cleaved Asp214 antibody PARP-H8 at 0.1 µg/mL.




Fig-4: Western blot analysis of HeLa cell extract untreated or treated with staurosporine using 0.001 µg/mL Cleaved PARP (Asp214) antibody PARP-H8 or Company C antibody at 0.05 µg/mL (manufacturer's recommended concentration) developed using the same exposure.




Fig-5: Flow cytometric analysis of SK.N.MC cells secondary antibody only negative control (blue) or untreated (red) or treated with staurosporine (green) using PARP, Cleaved Asp214 antibody PARP-H8 or Company C antibody at 0.1 µg/mL (manufacturer's recommended concentration).